Is Palantir Stock a Millionaire Maker?
Palantir (NASDAQ:PLTR) has shot upward over the last year and…
Buy
64
CDTX Quote, Financials, Valuation and Earnings
Last price:
$21.81
Seasonality move
:
-0.43%
Day range:
$20.80 - $22.80
52-week range:
$10.14 - $28.42
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
6.69x
P/B ratio:
1.60x
Volume:
59.4K
Avg. volume:
178.9K
1-year change:
84.17%
Market cap:
$262M
Revenue:
$1.3M
EPS (TTM):
-$30.09
Analysts' Opinion
-
Consensus RatingCidara Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $36.60, Cidara Therapeutics has an estimated upside of 75.25% from its current price of $21.75.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $33.00 representing -58.01% downside risk from its current price of $21.75.
Fair Value
-
According to the consensus of 2 analysts, Cidara Therapeutics has 75.25% upside to fair value with a price target of $36.60 per share.
CDTX vs. S&P 500
-
Over the past 5 trading days, Cidara Therapeutics has underperformed the S&P 500 by -5.39% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Cidara Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Cidara Therapeutics revenues have been falling on a year-over-year basis for 5 quarters in a row. In the most recent quarter Cidara Therapeutics reported revenues of $302K.
Earnings Growth
-
Cidara Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Cidara Therapeutics reported earnings per share of -$5.37.
Enterprise value:
72.2M
EV / Invested capital:
--
Price / LTM sales:
6.69x
EV / EBIT:
--
EV / Revenue:
3.48x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-0.41x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-134.09%
Net Income Margin (TTM):
-185.55%
Return On Equity:
-443.37%
Return On Invested Capital:
-443.37%
Operating Margin:
-3675.83%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $64.4M | $43.2M | -- | $2.8M | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$33.5M | -$17.1M | -$93.4M | -$8.7M | -$54.2M | |
| EBITDA | -$33.1M | -$17M | -$93.1M | -$8.7M | -$54.1M | |
| Diluted EPS | -$9.60 | -$5.13 | -$30.09 | -$0.69 | -$5.37 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $57.2M | $71.7M | $45.1M | $60.9M | $210.7M | |
| Total Assets | $60.4M | $75.3M | $47.5M | $67M | $214.8M | |
| Current Liabilities | $38.6M | $34M | $41.4M | $67.4M | $49.6M | |
| Total Liabilities | $49.7M | $53.8M | $61.9M | $75.2M | $51.5M | |
| Total Equity | $10.7M | $21.6M | -$14.4M | -$8.2M | $163.3M | |
| Total Debt | $7M | $2.6M | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$28.5M | -$22.4M | -$176.5M | -$12.7M | -$29.4M | |
| Cash From Investing | -$118K | -$505K | -$129K | -$178K | -- | |
| Cash From Financing | -$951K | $26M | $337.1M | $8K | $98.2M | |
| Free Cash Flow | -$28.6M | -$22.9M | -$176.7M | -$12.9M | -$29.4M | |
CDTX
Sector
Market Cap
$262M
$35.8M
Price % of 52-Week High
73.49%
45.16%
Dividend Yield
0%
0%
Shareholder Yield
-438.47%
-0.82%
1-Year Price Total Return
74.33%
-38.63%
Beta (5-Year)
0.864
0.660
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$21.46
200-day SMA
Buy
Level
$17.25
Bollinger Bands (100)
Buy
Level
19.43 - 24.03
Chaikin Money Flow
Sell
Level
-1.7M
20-day SMA
Buy
Level
$19.52
Relative Strength Index (RSI14)
Buy
Level
57.11
ADX Line
Buy
Level
16.34
Williams %R
Neutral
Level
-30.6413
50-day SMA
Buy
Level
$21.15
MACD (12, 26)
Buy
Level
0.26
25-day Aroon Oscillator
Buy
Level
44
On Balance Volume
Neutral
Level
3.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-2.3543)
Sell
CA Score
(Annual)
Level (-5.865)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (7.1143)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company’s portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
Stock Forecast FAQ
In the current month, CDTX has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CDTX average analyst price target in the past 3 months is $36.60.
-
Where Will Cidara Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Cidara Therapeutics share price will rise to $36.60 per share over the next 12 months.
-
What Do Analysts Say About Cidara Therapeutics?
Analysts are divided on their view about Cidara Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Cidara Therapeutics is a Sell and believe this share price will drop from its current level to $33.00.
-
What Is Cidara Therapeutics's Price Target?
The price target for Cidara Therapeutics over the next 1-year time period is forecast to be $36.60 according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CDTX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Cidara Therapeutics is a Buy. 2 of 2 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CDTX?
You can purchase shares of Cidara Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Cidara Therapeutics shares.
-
What Is The Cidara Therapeutics Share Price Today?
Cidara Therapeutics was last trading at $21.81 per share. This represents the most recent stock quote for Cidara Therapeutics. Yesterday, Cidara Therapeutics closed at $21.75 per share.
-
How To Buy Cidara Therapeutics Stock Online?
In order to purchase Cidara Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is QuantumScape a Buy Now?
QuantumScape (NYSE:QS) is an innovative EV battery company that specializes…
Is Vertex Stock Still a Good Buy?
Over the past ten years or so, Vertex Pharmaceuticals (NASDAQ:…
Stock Ideas
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Sell
50
RGC alert for May 1
Regencell Bioscience Holdings [RGC] is up 20.58% over the past day.
Sell
38
WGS alert for May 1
GeneDx Holdings [WGS] is down 6.85% over the past day.
Sell
43
VICR alert for May 1
Vicor [VICR] is down 1.28% over the past day.
